Inhalable Imatinib Formulations for Pulmonary Arterial Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) using imatinib are limited by severe adverse events and require high doses for effective lung exposure, which can be mitigated by developing inhalable formulations of imatinib with controlled crystal forms and delivery mechanisms.
Innovation Solution
Inhalable formulations of imatinib with greater than 80% single crystal form, micronized to achieve deep lung penetration, and processed to exclude amorphous content, allowing for controlled dosing and predictable patient response, thereby reducing systemic adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of imatinib are administered orally or intravenously to achieve effective lung exposure, then therapeutic efficacy is improved, but systemic adverse events increase
Solution Approach 1:
The invention segments the drug delivery system by using inhalable particles that target the lungs specifically, separating the therapeutic action at the target site from systemic circulation. This allows high local concentrations in the lungs while minimizing systemic exposure and associated adverse events.
Solution Approach 2:
The invention applies local quality by creating a formulation with specific crystal forms and particle size ranges (0.5-5 μm) that optimize lung deposition and absorption. The controlled crystal form ensures predictable solubility and absorption characteristics specifically at the lung site, achieving therapeutic efficacy without proportionally increasing systemic adverse events.
2Ease of operation
If conventional oral formulations are used to treat PAH, then ease of administration is maintained, but lung exposure is insufficient requiring high systemic doses
Solution Approach 1:
The invention utilizes pneumatic principles through inhalation delivery, where the patient breathes in the suspended particles through a nebulizer or inhalation device. This leverages the natural respiratory airflow to deliver the drug directly to the lungs, maintaining ease of administration while dramatically improving lung exposure compared to oral routes.
3Measurement precision
If imatinib is micronized to achieve deep lung penetration, then delivery precision to target tissue is improved, but manufacturing complexity increases
Solution Approach 1:
The invention applies parameter changes by controlling particle size to a specific range (0.5-5 μm) and maintaining defined crystal forms. These parameter specifications optimize pulmonary deposition and absorption while providing predictable pharmacokinetics. The manufacturing process uses established micronization techniques with quality control focused on these key parameters.
4Ease of manufacture
If multiple crystal forms of imatinib are present in the formulation, then manufacturing flexibility is improved, but dosing predictability decreases
Solution Approach 1:
The invention applies local quality by selecting and maintaining a specific crystal form (or limited set of crystal forms) in the inhalable formulation. This ensures predictable solubility, dissolution, and absorption characteristics in the lung environment, providing dosing predictability while still allowing manufacturing flexibility in choosing which stable crystal form to use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhalable formulations provide higher lung exposure with lower systemic doses, reducing adverse events and enabling effective treatment of PAH and other pulmonary cardiovascular conditions while maintaining therapeutic efficacy.
Implementation Method 1
Inhalable formulations of imatinib with greater than 80% single crystal form, micronized to achieve deep lung penetration
Implementation Method 2
micronized to achieve deep lung penetration
Implementation Method 3
allowing for controlled dosing and predictable patient response
Data Source
AI summary
The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.